牛牛AI助理已提取核心訊息
John J. Sperzel III, associated with T2 Biosystems, Inc. [TTOO], executed a transaction on February 20, 2024, involving the acquisition of 160 shares of common stock. This transaction was classified under the code 'M', indicating an exercise or conversion of derivative security. Following this transaction, Sperzel's direct holdings in T2 Biosystems have increased to a total of 333 shares. The transaction reflects a continued investment in the company by an individual with a remarked relationship to the issuer.
John J. Sperzel III, associated with T2 Biosystems, Inc. [TTOO], executed a transaction on February 20, 2024, involving the acquisition of 160 shares of common stock. This transaction was classified under the code 'M', indicating an exercise or conversion of derivative security. Following this transaction, Sperzel's direct holdings in T2 Biosystems have increased to a total of 333 shares. The transaction reflects a continued investment in the company by an individual with a remarked relationship to the issuer.
與T2 Biosystems, Inc. [TTOO] 相關的約翰·斯佩爾澤爾三世於2024年2月20日執行了一項交易，涉及收購160股普通股。該交易被歸類爲'M'，表示行使或轉換衍生證券。在這筆交易之後，斯佩爾澤爾在T2 Biosystems的直接持股量已增加到總共333股。該交易反映了與發行人有特殊關係的個人對該公司的持續投資。
與T2 Biosystems, Inc. [TTOO] 相關的約翰·斯佩爾澤爾三世於2024年2月20日執行了一項交易，涉及收購160股普通股。該交易被歸類爲'M'，表示行使或轉換衍生證券。在這筆交易之後，斯佩爾澤爾在T2 Biosystems的直接持股量已增加到總共333股。該交易反映了與發行人有特殊關係的個人對該公司的持續投資。
有用
沒用
該公告為獨立文件：